Overexpression of p53 in tall cell variants of papillary thyroid carcinoma

A. Ruter, J. Dreifus, M. Jones, R. Nishiyama, S. Lennquist, Ian D Hay, A. R. Shaha, N. W. Thompson, O. H. Clark

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background. The tall cell variant (TCV) is a clinically aggressive subtype of papillary thyroid cancer. The aim of this study was to discover the prevalence of mutant forms of p53 protein in this subtype and relate it to clinical outcome. Methods. Eighteen patients with TCV and a control group with common papillary cancers, matched for age and gender, were studied. The p53 mutations were identified by means of immunohistochemical staining. Data reviewed were overall survival, recurrence, TNM stage, and p53 positivity. Results. p53 mutations occurred in 11 (61%) patients with TCV compared with two (11%) in control group (p = 0.05). In the TCV group two patients died of the disease (11%) and eight (44%) had local recurrences or distant metastases compared with none in the control group. All deaths and 70% of the recurrences occurred in patients with stage III or IV disease. p53 positivity did not correlate with any reduction in survival (7% compared with 9%) but with increased rate of local (23% compared with 4%) and distant (23% compared with 13%) recurrences. Conclusions. TCV was associated with a significantly higher rate of p53 positivity than common papillary carcinoma. The stage of the disease seemed to be a better prognostic indicator than p53 positivity for overall survival.

Original languageEnglish (US)
Pages (from-to)1046-1050
Number of pages5
JournalSurgery
Volume120
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Recurrence
Control Groups
Survival
Mutation
Papillary Carcinoma
Papillary Thyroid cancer
Staining and Labeling
Neoplasm Metastasis
Neoplasms
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Ruter, A., Dreifus, J., Jones, M., Nishiyama, R., Lennquist, S., Hay, I. D., ... Clark, O. H. (1996). Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery, 120(6), 1046-1050.

Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. / Ruter, A.; Dreifus, J.; Jones, M.; Nishiyama, R.; Lennquist, S.; Hay, Ian D; Shaha, A. R.; Thompson, N. W.; Clark, O. H.

In: Surgery, Vol. 120, No. 6, 1996, p. 1046-1050.

Research output: Contribution to journalArticle

Ruter, A, Dreifus, J, Jones, M, Nishiyama, R, Lennquist, S, Hay, ID, Shaha, AR, Thompson, NW & Clark, OH 1996, 'Overexpression of p53 in tall cell variants of papillary thyroid carcinoma', Surgery, vol. 120, no. 6, pp. 1046-1050.
Ruter A, Dreifus J, Jones M, Nishiyama R, Lennquist S, Hay ID et al. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery. 1996;120(6):1046-1050.
Ruter, A. ; Dreifus, J. ; Jones, M. ; Nishiyama, R. ; Lennquist, S. ; Hay, Ian D ; Shaha, A. R. ; Thompson, N. W. ; Clark, O. H. / Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. In: Surgery. 1996 ; Vol. 120, No. 6. pp. 1046-1050.
@article{00bddff6416945f2afac0c11afb173a8,
title = "Overexpression of p53 in tall cell variants of papillary thyroid carcinoma",
abstract = "Background. The tall cell variant (TCV) is a clinically aggressive subtype of papillary thyroid cancer. The aim of this study was to discover the prevalence of mutant forms of p53 protein in this subtype and relate it to clinical outcome. Methods. Eighteen patients with TCV and a control group with common papillary cancers, matched for age and gender, were studied. The p53 mutations were identified by means of immunohistochemical staining. Data reviewed were overall survival, recurrence, TNM stage, and p53 positivity. Results. p53 mutations occurred in 11 (61{\%}) patients with TCV compared with two (11{\%}) in control group (p = 0.05). In the TCV group two patients died of the disease (11{\%}) and eight (44{\%}) had local recurrences or distant metastases compared with none in the control group. All deaths and 70{\%} of the recurrences occurred in patients with stage III or IV disease. p53 positivity did not correlate with any reduction in survival (7{\%} compared with 9{\%}) but with increased rate of local (23{\%} compared with 4{\%}) and distant (23{\%} compared with 13{\%}) recurrences. Conclusions. TCV was associated with a significantly higher rate of p53 positivity than common papillary carcinoma. The stage of the disease seemed to be a better prognostic indicator than p53 positivity for overall survival.",
author = "A. Ruter and J. Dreifus and M. Jones and R. Nishiyama and S. Lennquist and Hay, {Ian D} and Shaha, {A. R.} and Thompson, {N. W.} and Clark, {O. H.}",
year = "1996",
language = "English (US)",
volume = "120",
pages = "1046--1050",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Overexpression of p53 in tall cell variants of papillary thyroid carcinoma

AU - Ruter, A.

AU - Dreifus, J.

AU - Jones, M.

AU - Nishiyama, R.

AU - Lennquist, S.

AU - Hay, Ian D

AU - Shaha, A. R.

AU - Thompson, N. W.

AU - Clark, O. H.

PY - 1996

Y1 - 1996

N2 - Background. The tall cell variant (TCV) is a clinically aggressive subtype of papillary thyroid cancer. The aim of this study was to discover the prevalence of mutant forms of p53 protein in this subtype and relate it to clinical outcome. Methods. Eighteen patients with TCV and a control group with common papillary cancers, matched for age and gender, were studied. The p53 mutations were identified by means of immunohistochemical staining. Data reviewed were overall survival, recurrence, TNM stage, and p53 positivity. Results. p53 mutations occurred in 11 (61%) patients with TCV compared with two (11%) in control group (p = 0.05). In the TCV group two patients died of the disease (11%) and eight (44%) had local recurrences or distant metastases compared with none in the control group. All deaths and 70% of the recurrences occurred in patients with stage III or IV disease. p53 positivity did not correlate with any reduction in survival (7% compared with 9%) but with increased rate of local (23% compared with 4%) and distant (23% compared with 13%) recurrences. Conclusions. TCV was associated with a significantly higher rate of p53 positivity than common papillary carcinoma. The stage of the disease seemed to be a better prognostic indicator than p53 positivity for overall survival.

AB - Background. The tall cell variant (TCV) is a clinically aggressive subtype of papillary thyroid cancer. The aim of this study was to discover the prevalence of mutant forms of p53 protein in this subtype and relate it to clinical outcome. Methods. Eighteen patients with TCV and a control group with common papillary cancers, matched for age and gender, were studied. The p53 mutations were identified by means of immunohistochemical staining. Data reviewed were overall survival, recurrence, TNM stage, and p53 positivity. Results. p53 mutations occurred in 11 (61%) patients with TCV compared with two (11%) in control group (p = 0.05). In the TCV group two patients died of the disease (11%) and eight (44%) had local recurrences or distant metastases compared with none in the control group. All deaths and 70% of the recurrences occurred in patients with stage III or IV disease. p53 positivity did not correlate with any reduction in survival (7% compared with 9%) but with increased rate of local (23% compared with 4%) and distant (23% compared with 13%) recurrences. Conclusions. TCV was associated with a significantly higher rate of p53 positivity than common papillary carcinoma. The stage of the disease seemed to be a better prognostic indicator than p53 positivity for overall survival.

UR - http://www.scopus.com/inward/record.url?scp=0029907082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029907082&partnerID=8YFLogxK

M3 - Article

VL - 120

SP - 1046

EP - 1050

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -